Summary
This Form 8-K filing by DexCom, Inc. (DXCM) on May 5, 2011, primarily reports on a material definitive agreement related to a significant equity offering. DexCom entered into an Underwriting Agreement with Canaccord Genuity Inc. for the sale of up to 4,700,000 shares of its common stock. The offering, priced at $15.189 per share to the underwriter and including an overallotment option of 705,000 shares, is being conducted under a shelf registration statement. This action signals DexCom's intent to raise capital, likely to fund its operations, research and development, or expansion efforts. Investors should note the closing date of May 10, 2011, as a key event to monitor for the completion of this capital raise.
Key Highlights
- 1DexCom entered into an Underwriting Agreement with Canaccord Genuity Inc. on May 4, 2011.
- 2The agreement facilitates the sale of up to 4,700,000 shares of DexCom common stock.
- 3The offering price to the underwriter is $15.189 per share.
- 4An overallotment option for 705,000 shares is included in the offering.
- 5The shares are being offered under a shelf registration statement (Form S-3) and prospectus supplement.
- 6The offering is expected to close on May 10, 2011.
- 7The filing includes a legal opinion from Fenwick & West LLP regarding the legality of the offered shares.
Frequently Asked Questions
The primary purpose of this 8-K filing is to report DexCom, Inc.'s entry into a material definitive agreement, specifically an Underwriting Agreement for a secondary offering of its common stock.
DexCom is offering up to 4,700,000 shares of its common stock. The price to the underwriter is $15.189 per share. This total includes an overallotment option of 705,000 shares.
Canaccord Genuity Inc. is the underwriter for this offering.
The offering is expected to close on May 10, 2011.